TXG 10x Genomics, Inc. | US88025U1097
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 671.472.950 | 614.062.070 | 9.35% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 0,21 | 0,00 | -- |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 3 | 2 | 50.00% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |